March 1, 2021
Business News

AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients


SEONGNAM, South Korea–()–AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients were enrolled, and 171 (81.4%) subjects completed 6-month dosing in the study.

“We are pleased to report the achievement of this critical milestone, and AriBio is looking forward to announcing the topline results by the end of Q1’2021. Despite the challenges presented by the COVID-19 pandemic, we were able to complete dosing and follow-up assessments in this trial….



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
NEW Large Smartphone Manufacturer Signs Software License Contract With Elliptic Labs
Median Technologies fera un point d’avancement par webcast le 9 mars 2021
Median Technologies to Host a Live Webcast and Provide a Company Update on March 9th, 2021